Search Results

MC# 19-05
A Phase Ib/II, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

MC# 19-16
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib or Docetaxel/Prednisone Plus Afuresertib in Patients with Metastatic Castration Resistant Prostate Cancer Following Standard of Care Treatment

MC# 21-09
A Phase I/II, Open-Label, Dose Escalation, and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients with Metastatic Castration Resistant Prostate Cancer

MC# 21-13
A Phase II Study of the Hepcidin Mimetic PTG-300 in Patients With Phlebotomy-Requiring Polycythemia Vera

MC# 21-16
A Phase II Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor

MC# 21-22
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Trial (1-Better) Examining Xb2001 (Anti-Il-1⍺ True Human Antibody) In Combination With Onivyde + 5-Fluorouracil + Leucovorin In Advanced Pancreatic Cancer

MC# 21-28
A Phase I/II Dose Escalation and Dose Expansion Study of BA3011 Alone and in Combination with Nivolumab in Adult and Adolescent Patients 12 Years and Older with Advanced Solid Tumors

MC# 21-35
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients with Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients with KRAS-Mutated Non Small Cell Lung Cancer

MC# 21-45
A Phase I Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select Advanced Solid Tumors

MC# 22-21
A Phase I, Open-label, Multi-center, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies

MC# 18-22
A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Advanced Solid Tumors. Sub-study to Characterize the Effects of Tinostamustine at a Dose of 80 mg/m2 Administered during a 80-minute Infusion on Cardiac Repolarization in Patients with Advanced Solid Tumors

MC# 20-23
An Open-Label, Multicenter Phase I/II Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors

MC# 20-26
Tumor-Agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

MC# 20-40
A Phase I Multi-Country, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1811 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects

MC# 21-04
A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects with Refractory Solid Tumors

MC# 21-12
An Exploratory Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of ON 123300 Capsules Administered Orally as Escalating Daily Doses in Patients with Advanced Cancer Relapsed or Refractory to at Least One (1) Prior Line of Therapy

MC# 21-15
An Open-Label, Phase I/II Study to Evaluate Safety, Efficacy, Pharmacokinetics of EU101, an Agonistic Anti-CD137 (4-1BB) Monoclonal Antibody in Patients with Advanced Solid Tumors

MC# 21-21
A Phase Ib/II, Open-label, Multi-center Study of ERAS-007 ERK Inhibitor in Patients with Advanced or Metastatic Solid Tumors

MC# 21-25
An Open Label, Phase I Dose Escalation Trial, with Dose Confirmation and Expansion, of BI 1810631 as Monotherapy in Patients with Advanced or Metastatic Solid Tumors with HER2 Aberrations

MC# 21-26
A Phase I, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients with Relapsed or Refractory Malignancies

MC# 21-27
A Phase Ia/Ib, Open-Label, Multicentre Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of BI 1823911 as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors Expressing KRAS G12C Mutation

MC# 21-29
A Phase I Study to Evaluate the Safety and Tolerability of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination with Pembrolizumab in Adults with Advanced Solid Tumors

MC# 21-30
An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid Tumours

MC# 21-34
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Subjects with Advanced Solid Tumors

MC# 21-37
A Phase I, First in Human, Open-label, Dose Escalation and Dose Expansion Study of TST005 in Patients with Locally Advanced or Metastatic Solid Tumors